Prediction of residual liver hypertrophy by liver iodine map

JRCT ID: jRCT1041210088

Registered date:22/10/2021

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Primary or metastatic liver cancer or biliary tract cancer
• Date of first enrollment: 11/11/2021
• Target sample size: 199
• Study type: Interventional
• Intervention(s): Two dual enrgy CT scans, simple CT and contrast CT, during portal vein embolization

Outcome(s)

• Primary Outcome: Liver volumes of embolized and unembolized lobes and their rates of change before and after portal vein embolization
• Secondary Outcome: Complications due to portal vein embolization (e.g., liver dysfunction and portal vein thrombus), presence of liver failure after extended hepatectomy, length of hospital stay, and survival

Key inclusion & exclusion criteria

• Age minimum: Not applicable
• Age maximum: Not applicable
• Gender: Both

Include criteria

Patients with primary or metastatic liver cancer or biliary tract cancer who are scheduled for extended hepatectomy and will undergo portal vein embolization
Written consent must be obtained.

Exclude criteria

contraindicated patients for iodine contrast administration
Decreased renal function (eGFR less than 30 mL/min/1.73m2)

Related Information

• Primary Sponsor: Komada Tomohiro
• Source(s) of Monetary Support: Grant-in-Aid for Scientific Research